PLIANT THERAPEUTICS, INC. Proceeds from Debt, Net of Issuance Costs
PLIANT THERAPEUTICS, INC. (PLRX) reported Proceeds from Debt, Net of Issuance Costs of $9.85 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2023-03-09
- PLIANT THERAPEUTICS, INC. proceeds from debt, net of issuance costs for fiscal 2022 was $9.85M.
- PLIANT THERAPEUTICS, INC. proceeds from debt, net of issuance costs for fiscal 2021 was $0.00.
| Period end | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|
| 2022-12-31 | $9.85M 10-K · filed 2023-03-09 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |